Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKeyur DesaiCBChad C. BjorklundJHJoseph T. Hadala

Discussion

Loading...

Member takes

Overview

Pharmacodynamic analyses reveal significant tumor responses in multiple myeloma patients with high-risk TP53 mutations, indicating clinical efficacy of mezigdomide treatment.

Key Points

  • Patients receiving mezigdomide plus dexamethasone showed enhanced progression-free survival related to biomarker changes.
  • Bone marrow and blood samples were analyzed to assess pharmacodynamic activities and tumor burden markers.
  • Whole-genome sequencing revealed key insights into genetic features impacting treatment response and efficacy.
  • Cereblon expression and TP53 mutations were critical to understanding the therapeutic potential in high-risk scenarios.

Cite This Study

Desai et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3fahttps://doi.org/10.1182/blood-2025-5697
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 1 citations
  2. 2Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series2025 · 2 citations
  3. 3EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma2025
  4. 4Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma2025
  5. 5Mezigdomide overcomes CRBN mutations emerging post IMiD therapy2025